Allrock Bio develops oral, highly selective ROCK1/2 small‑molecule inhibitors to treat rare cardiopulmonary diseases such as pulmonary arterial hypertension and associated fibrotic lung conditions. By integrating pre‑clinical data, Phase 1 PK/PD modeling, and biomarker‑driven trial designs, the company accelerates the clinical development of disease‑modifying therapies for pharmaceutical partners and healthcare providers.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
WVFounders
Product
Problem
Patients with rare cardiopulmonary diseases such as pulmonary hypertension and interstitial lung disease have limited treatment options, and the development of new therapies is often slowed by complex clinical trial design, regulatory hurdles, and fragmented expertise.
Solution
Allrock Bio focuses on accelerating the development of novel small‑molecule therapies for cardiopulmonary indications. Leveraging deep drug‑development experience, the company designs streamlined clinical programs that efficiently demonstrate safety, pharmacodynamics, and efficacy. Its lead candidate, ROC‑101, is an oral, highly selective ROCK1/2 inhibitor that targets the proliferative, inflammatory, and fibrotic pathways underlying pulmonary arterial hypertension and related fibrotic lung disease. By integrating pre‑clinical data, Phase 1 pharmacokinetic/pharmacodynamic modeling, and partnerships with global experts, Allrock Bio aims to advance ROC‑101 through Phase 2a and beyond, addressing an unmet need for disease‑modifying treatments in this patient population.
Target Audience
Primary customers are pharmaceutical partners, clinical research organizations, and healthcare providers seeking disease‑modifying therapies for pulmonary hypertension, PAH‑associated interstitial lung disease, and other fibrotic cardiopulmonary conditions.
Features
- Oral, bioavailable small‑molecule ROCK1/2 inhibitor with demonstrated plasma exposure and target engagement in Phase 1 studies
- Dual anti‑proliferative, anti‑inflammatory, and anti‑fibrotic mechanism addressing pulmonary arterial remodeling and fibrosis
- Clinical development strategy that incorporates comprehensive trial planning, adaptive dosing, and biomarker‑driven endpoints
- Partnerships with leading academic and industry experts to inform study design and regulatory pathways
- Focus on rare cardiopulmonary diseases, enabling targeted patient enrollment and accelerated regulatory review